NCT02612311Phase 3Terminated

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-02-22Actual
Enrollment · participants603Actual
Source updated2024-12-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview